경동제약

I.R.

Company credited for technology, KyungDong Pharm

Consolidated Statement of Financial Positio
Category	2017	2016	20165
Current Assets	110,127,126,172	112,480,392,730	85,607,304,024
Non-Current Assets	141,300,419,088	126,007,690,337	147,803,105,989
Total Assets	251,427,545,260	238,488,083,067	233,410,410,013
Current Liabilities	29,908,481,576	27,194,063,058	20,500,653,092
Non-Current Liabilities	2,170,902,935	2,722,550,362	8,470,178,176
Total Liabilities	32,079,384,511	29,916,613,420	28,970,831,268
Issued Capital	13,575,000,000	13,575,000,000	13,575,000,000
Capital Surplus	8,475,671,631	8,307,140,697	8,307,140,697
Elements of Other Stockholder’s Equity	-22,448,862,404	-22,898,797,104	-20,125,695,214
Comprehensive Income/Loss Accumulated	7,482,839,803	9,540,702,204	12,606,266,140
Retained Earnings	213,870,009,465	201,402,761,784	190,772,490,562
Non-Controlling Interests	-1,606,497,746	-1,355,337,934	-695,623,440
Total Equity	219,348,160,749	208,571,469,647	208,571,469,647

Consolidated Statement of Comprehensive Income
Category	2017	2016	20165
Sales	177,772,468,130	158,599,150,940	151,893,327,055
Cost of Sales	74,431,737,257	63,629,895,014	61,250,496,065
Gross Profit	103,340,730,873	94,969,255,926	90,642,830,990
Technology Development Expenses	4,594,476,869	4,120,005,444	4,637,904,320
Selling General Administrative Expenses	67,837,230,068	64,573,790,560	59,985,429,956
Operating Profit	30,909,023,936	26,275,459,922	26,019,496,714
Profit (loss) Before Tax	30,234,638,640	24,981,231,843	20,852,429,408
Income Tax Expense	10,008,370,631	8,031,819,800	7,575,180,416
Profit (Loss)	20,226,268,009	16,949,412,043	13,277,248,992